| Literature DB >> 32148513 |
Rocio Del Pilar López Panqueva1,2, David A Suarez-Zamora1, Luis E Barrera-Herrera1, Mariam Rolón Cadena1,2.
Abstract
Merkel cell carcinoma (MCC) is a rare poorly differentiated neuroendocrine tumor, usually located in sun-exposed skin, with aggressive behavior and with high recurrence risk and metastatic disease. In Latin America, case series have been published, and it does not exceed 32 patients in 10 years, and in Colombia, there are case reports. We present a descriptive retrospective cross-sectional study in patients diagnosed with MCC in the Department of Pathology and Laboratories at the University Hospital Fundación Santa Fe de Bogotá(FSFB) between January 2003 and December 2018. We present the demographic, clinical, and pathological variables of these patients, as well as a literature review.Entities:
Year: 2020 PMID: 32148513 PMCID: PMC7049825 DOI: 10.1155/2020/8391510
Source DB: PubMed Journal: Case Rep Med
Patient characteristics.
| Patient ID | Age | Sex | Regional localization | Specific localization | CK7 | CK20 | Chromo. | Sinapt. |
|---|---|---|---|---|---|---|---|---|
| 1 | 62 | F | External ear | Auricular pavilion | − | + | + | + |
| 2 | 81 | M | External ear | Auricular pavilion | − | + | + | + |
| 3 | 57 | F | Skin face | Eyelid | ND | + | + | + |
| 4 | 60 | M | Skin face | Forehead | + | − | ND | + |
| 5 | 64 | F | Skin face | Cheekbone | − | + | ND | + |
| 6 | 65 | M | Skin face | Eyelid | − | + | + | ND |
| 7 | 74 | F | Skin face | Cheekbone | − | + | + | ND |
| 8 | 75 | M | Skin face | Cheekbone | ND | + | ND | + |
| 9 | 76 | F | Skin face | Cheekbone | ND | + | + | + |
| 10 | 77 | M | Skin face | Eyelid | ND | + | + | ND |
| 11 | 84 | M | Skin face | Forehead | − | + | + | + |
| 12 | 86 | M | Skin face | Forehead | ND | + | − | ND |
| 13 | 17 | F | Skin LLH | Finger | + | + | + | ND |
| 14 | 56 | F | Skin LLH | Thigh | − | + | + | + |
| 15 | 73 | F | Skin LLH | Thigh | − | + | + | + |
| 16 | 83 | F | Skin LLH | Thigh | ND | ND | ND | ND |
| 17 | 86 | M | Skin LLH | Thigh | ND | + | + | + |
| 18 | 49 | M | Skin NOS | — | − | + | + | ND |
| 19 | 82 | M | Skin NOS | — | − | + | + | ND |
| 20 | 87 | M | Skin NOS | — | ND | + | ND | ND |
| 21 | 72 | M | Skin ScNk | Neck | − | + | + | + |
| 22 | 86 | F | Skin ScNk | Scalp | − | + | + | + |
| 23 | 87 | M | Skin ScNk | Scalp | − | − | ND | + |
| 24 | 32 | F | Skin UPLS | Arm | − | + | + | ND |
| 25 | 61 | F | Skin UPLS | Arm | − | + | + | + |
| 26 | 69 | F | Skin UPLS | Arm | ND | + | + | + |
| 27 | 74 | F | Skin UPLS | Arm | − | + | ND | + |
| 28 | 48 | M | UNKPO | - | − | + | + | − |
| 29 | 56 | M | UNKPO | - | − | + | + | + |
| 30 | 64 | F | UNKPO | - | − | + | + | + |
| 31 | 70 | M | UNKPO | - | − | + | − | ND |
| 32 | 71 | M | UNKPO | - | − | − | + | + |
| 33 | 71 | M | UNKPO | - | − | + | + | + |
| 34 | 71 | M | UNKPO | - | − | + | − | + |
| 35 | 76 | M | UNKPO | - | − | + | + | + |
| 36 | 81 | F | UNKPO | - | ND | − | − | + |
UNKPO, unknown primary origin; skin NOS, skin not otherwise specified; skin UPLS, skin, upper limb, and shoulder; skin LLH, skin, lower limb, and hip; skin ScNk, skin, scalp, and neck; ND, no data.
Figure 1Tumor localization.
Population.
| Characteristics |
|
|---|---|
| Sex | |
| Male | 20 (55.6%) |
| Female | 16 (44.4%) |
|
| |
| Age, years | |
| Median | 68.97 |
| Range | 17–87 |
|
| |
| Localization | |
| Primary site unknown | 9 (25%) |
| Skin without other specification | 3 (8.3%) |
| Head and neck | 15 (41.7%) |
|
| |
| Upper limb | 4 (11.1%) |
| Lower limb | 5 (13.9%) |
| Ck 7 | Positive 2 (5.6%) |
| Ck-20 | Positive 33 (91.1%) |
| Chromo./sinapt. | Positive 32 (88.9%) |
Localization by sex.
| Localization | Sex | |
|---|---|---|
| Female | Male | |
| Unknown primary | 2 (12.5%) | 7 (35%) |
| Skin without specification | 0 (0%) | 3 (15%) |
| Head and neck | 6 (37.5%) | 9 (45%) |
| Superior member | 4 (25%) | 0 (0%) |
| Inferior member | 4 (25%) | 1 (5%) |
| Total | 16 | 20 |
Figure 2Distribution by sex.
Neuroendocrine markers vs. CK-20 status.
| Neuroendocrine markers | ||
|---|---|---|
| Negative | Positive | |
| CK-20 | ||
|
| 0 | 2 (6.2%) |
|
| 2 (100%) | 30 (93.8%) |
| Total | 2 | 32 |